Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Martin-Broto

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
JAMA Oncology|March 30, 2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical TrialRoberta Sanfilippo, Nadia Hindi, Josefina Cruz Jurado, et al.
Cancers|February 9, 2021
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study ProtocolDide den Hollander, Marco Fiore, Javier Martin-Broto, et al.
Molecular Oncology|May 26, 2025
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcomaPiotr J Manasterski, Molly R Danks, John P Thomson, et al.
Oncotarget|May 1, 2018
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patientsDavid S Moura, Rafael Ramos, Antonio Fernandez-Serra, et al.
Cancer Medicine|July 18, 2022
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 studyAnna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, et al.
Cancers|September 9, 2022
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with PazopanibSamuel Hidalgo-Ríos, Jaime Carrillo-García, David S Moura, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
JAMA Oncology|March 30, 2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical TrialRoberta Sanfilippo, Nadia Hindi, Josefina Cruz Jurado, et al.
Cancers|February 9, 2021
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study ProtocolDide den Hollander, Marco Fiore, Javier Martin-Broto, et al.
Molecular Oncology|May 26, 2025
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcomaPiotr J Manasterski, Molly R Danks, John P Thomson, et al.
Oncotarget|May 1, 2018
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patientsDavid S Moura, Rafael Ramos, Antonio Fernandez-Serra, et al.
Cancer Medicine|July 18, 2022
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 studyAnna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, et al.
Cancers|September 9, 2022
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with PazopanibSamuel Hidalgo-Ríos, Jaime Carrillo-García, David S Moura, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Pageof 12